Page 4 - KIDNEY CANCER
P. 4
Background
• pRCC is a rare malignancy, constituting 15% of cases of renal cell carcinoma 1
• VEGF-directed therapies for clear cell RCC such as sunitinib have previously
constituted the standard of care in metastatic pRCC
Agent N RR PFS Notes
Sunitinib 2 41 5% 7.6 mos • Retrospective analysis
• Included both papillary (n=41) and chromophobe (n=12)
Sunitinib 3 27 0% 1.6 mos • Prospective analysis
• Included papillary (n=27) and other non-clear cell types (n=30)
Sunitinib 4 33 24% 8.1 mos • Prospective analysis, randomized versus everolimus
• Included papillary (n=70) and other non-clear cell types (n=39)
Sunitinib 5 61 13% a 6.6 mos a • Prospective analysis
11% b 5.5 mos b • Included both type I (n=15) and type II (n=46) papillary
3
5
1 Zhang T et al Am Soc Clin Oncol Educ Book 2017; 37:337-42; Choueiri TK et al J Clin Oncol. 2008 Jan 1;26(1):127-31; Tannir NM et al Urology. 2012;62(6):1013-9; Armstrong AJ et al, Lancet Oncol, 2016; 17: 378-88; Ravaud A et
2
4
al Ann Oncol. 2012;23(Suppl 9):Abstr 707PD; Type I papillary; Type II papillary
a
b
